Clinical Trials Logo

Filter by:
NCT ID: NCT06432244 Completed - Thyroid Cancer Clinical Trials

The Effect of the Number of Central Lymph Nodes on Changes in Parathyroid Function

Start date: January 1, 2020
Phase:
Study type: Observational

This study collected data from patients who underwent thyroidectomy in the Breast and Thyroid Surgery Department of Shandong Provincial Hospital from January 2020 to December 2023 by reviewing medical records. The main calculation indicator was the changes in PTH before and after surgery. This study grouped patients based on the number of central lymph nodes under postoperative paraffin pathology, and statistically analyzed the changes and differences in PTH before and after surgery in different groups to verify the relationship between the number of central lymph nodes in the thyroid gland and parathyroid function, and to provide reference for surgical selection in thyroid cancer patients with multiple cervical lymph node metastases.

NCT ID: NCT06432101 Completed - Clinical trials for Primary Sjögren's Syndrome

Acupuncture Combined With Hydroxychloroquine

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

To observe the clinical efficacy of acupuncture combined with hydroxychloroquine sulfate tablets on the symptoms of dry mouth and dry eyes in primary Sjögren's syndrome.

NCT ID: NCT06431438 Completed - Chronic Hepatitis B Clinical Trials

Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of TQA3810 Tablets

Start date: October 1, 2021
Phase: Phase 1
Study type: Interventional

This study was a single-center study, including randomized, double-blind, placebo-controlled, single-dose escalation study, multiple-dose study, food effect on pharmacokinetics and drug metabolism transformation study, drug interaction study. To evaluate the tolerability, pharmacokinetics and metabolic transformation of TQA3810 in healthy subjects after single or multiple doses of TQA3810, the drug-drug interactions between TQA3810 tablets and entecavir dispersible tablets, and the pharmacokinetic properties of TQA3810 tablets in combination.

NCT ID: NCT06429514 Completed - Depression Clinical Trials

Study on the Mechanism of Ganoderma Lucidum Spore Powder in the Treatment of Depression

Start date: March 28, 2023
Phase: N/A
Study type: Interventional

To clarify the clinical effect of Ganoderma lucidum spore powder intervention on postoperative depressive symptoms of papillary thyroid carcinoma ; to elucidate the antidepressant mechanism of Ganoderma lucidum spore powder.

NCT ID: NCT06429384 Completed - Clinical trials for Acute Ischemic Stroke

Y-3 Injection in the Treatment of Acute Ischemic Stroke Phase II Clinical Trial

Start date: June 4, 2023
Phase: Phase 2
Study type: Interventional

The objective of this clinical trial was to explore the efficacy and safety of Y-3 injection at different doses in patients with acute ischemic stroke within 48 hours of onset. A multicenter, randomized, double-blind, parallel, placebo-controlled trial design was designed to include 240 participants. Subjects press 1:1:1: 1 ratio of patients were randomly divided into Y-3 low-dose group (20 mg/ time, qd), medium-dose group (40 mg/ time, qd), high-dose group (60mg/ time, qd) and placebo control group, with 60 cases in each group. Random stratification factors include: Time of onset (≤24 hours, > 24 hours). The patients were treated for 10 consecutive days (10 times) and followed up to 90 days after the first dose. The trial was divided into three phases: screening/baseline, treatment, and follow-up. Screening/baseline period: Subjects enter the screening/baseline period for screening examination after signing the informed consent. Treatment period: Eligible subjects were randomly assigned at a ratio of 1:1:1:1 to receive Y-3 injection low-dose group, medium-dose group, high-dose group and placebo control drug for 10 consecutive days (10 times), during which relevant examinations required by the protocol were conducted and safety was assessed. Follow-up period: Participants who finished treatment were followed up until 90 days after the first dose. Stroke-related scale scores were performed at 10, 30, and 90 days after first use of the investigational drug The scores of Montgomery Depression Rating Scale (MSAS) and Hamilton Anxiety Scale (HAMA) were performed on the 10th and 90th days after the use of experimental drugs. Adverse events were recorded during treatment and follow-up to further assess safety

NCT ID: NCT06429306 Completed - Inflammation Clinical Trials

Study of Dexycu in Treating Intraocular Inflammation

Start date: August 22, 2022
Phase: Phase 3
Study type: Interventional

This is a phase III, prospective, randomised, double-masked, placebo-controlled, parallel-design, multicenter study of the efficacy, safety and pharmacokinetics of 9% dexamethasone intraocular injection for the treatment of inflammation associated with cataract surgery.

NCT ID: NCT06428110 Completed - Clinical trials for Warfarin Sodium Causing Adverse Effects in Therapeutic Use

A Prospective Cohort Study on Warfarin Personalized Medication

Start date: January 1, 2021
Phase:
Study type: Observational

Analyze the impact of the degree of blood vessel aging on the anticoagulant effect and bleeding risk of warfarin. Evaluating the possibility of using the degree of blood vessel aging to guide individualized use of the anticoagulant drug warfarin.

NCT ID: NCT06425276 Completed - Multiple Myeloma Clinical Trials

Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation

Start date: July 24, 2020
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to learn if high-dose Melphalan HCl for Injection works to treat multiple myeloma. It will also learn about the safety of high dose Melphalan HCl for Injection. The main questions it aims to answer are: Does high-dose Melphalan HCl for Injection deplete bone marrow activity which results in a better outcome of patients'own stem cell (blood-forming cell) transplantation? What medical problems do participants have when taking high-dose Melphalan HCl for Injection? How fast is the high-dose Melphalan HCl for Injection cleared out from blood? Participants will: - Take high-dose Melphalan HCl for Injection for 2 days - Have stem cell transplantation one day after treatment - Stay in the hospital for at least 10days and visit the clinic once every week for the first month after transplantation and every month after for checkups and tests.

NCT ID: NCT06424951 Completed - Meditation Clinical Trials

Kindness is Lesser Preferable Than Happiness: Investigating Interest in Different Effects of the Loving-kindness and Compassion Meditations

Start date: February 1, 2019
Phase: N/A
Study type: Interventional

As an initial step, Study 1 intended to compare the interest in different effects of LKCM among a convenient sample of university students. In order to separate different effects and close to application in real setting, the study will measure participants' interest in participating in proposed meditations, each of which aimed to generate one specific effect. The kind attitudes were represented by compassion for others, compassion for oneself, and appreciative joy for others, which were emphasized in the real LKCM trainings. The emotional well-being included increasing positive emotion, decreasing negative emotion and improving peacefulness, which were validated effects of LKCM. Other validated effects were also measured as fillers and used as additional explorations. The core hypothesis was that the interest in meditations on kind attitudes is significantly lower than interest in meditations on emotional well-being. The current study created a measure called Willingness to Participate in Meditation Trainings (WPMT). Participants rated their willingness to participate in nine meditation trainings that serve different purposes. Each meditation was rated by one item ("if the purpose of meditation training is to xxx, how much are you willing to participate?" where "xxx" indicates the purposes listed below) and was measured with a 100-mm Visual Analogue Scale (0 = totally unwilling to participate, 100 = totally willing to participate). Study 2 adopted WPMT in a 21-day online LKCM training. This make sure all participants really took part in meditation training, and allowed further exploration on how participants' WPMT were associated with the adherence and effects of training. To be more sensitive for the change during short training, the effects of training used state-like measures and still focused on two aspects: (1) personal happiness (happiness, sadness, peacefulness) which matched emotional well-being, and (2) interpersonal relationship (love, hate, gratitude) which reflected kind attitudes. The core hypotheses were that higher interest in meditations on Emotional Well-being and Kind attitudes predicted increases in personal happiness and interpersonal relationship, respectively.

NCT ID: NCT06424431 Completed - Pancreatectomy Clinical Trials

Methods of Pancreatic Stump Closure for Distal Pancreatectomy

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

The aim of this study is to conduct a retrospective analysis of patients who underwent distal pancreatectomy in our hospital, aiming to evaluate the safety and feasibility of two methods for closure of the pancreatic remnant: simple closure with a closure device and closure combined with electrocoagulation.